Z. Younossi, Q. M. Anstee, M. Marietti, T. Hardy, L. Henry et al., Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, vol.15, p.28930295, 2018.

H. Yki-jä-rvinen, Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome, Lancet Diabetes Endocrinol, vol.2, p.24731669, 2014.

Z. M. Younossi, A. B. Koenig, D. Abdelatif, Y. Fazel, L. Henry et al., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, vol.64, p.26707365, 2016.

K. L. Donnelly, C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt et al., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease, J Clin Invest, vol.115, p.15864352, 2005.

A. Kotronen, J. Westerbacka, R. Bergholm, K. H. Pietilä-inen, Y. Rvinen et al., Liver fat in the metabolic syndrome, J Clin Endocrinol Metab, vol.92, p.17595248, 2007.

S. Ballestri, S. Zona, G. Targher, D. Romagnoli, E. Baldelli et al., Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis, J Gastroenterol Hepatol, vol.31, p.26667191, 2016.

S. K. Park, M. H. Seo, H. C. Shin, and J. H. Ryoo, Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study, Hepatology, vol.57, p.23213066, 2013.

Q. M. Anstee, G. Targher, and C. P. Day, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis, Nat Rev Gastroenterol Hepatol, vol.10, p.23507799, 2013.

G. Bedogni, S. Bellentani, L. Miglioli, F. Masutti, M. Passalacqua et al., The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population, BMC Gastroenterol, vol.6, p.17081293, 2006.

B. L. Yang, W. C. Wu, K. C. Fang, Y. C. Wang, T. I. Huo et al., External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross sectional study in Taiwan, PLoS ONE, vol.10, issue.3, p.25781622, 2015.

E. M. Koehler, J. N. Schouten, B. E. Hansen, A. Hofman, B. H. Stricker et al., External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study, Clin Gastroenterol Hepatol, vol.11, p.23353640, 2013.

A. Gastaldelli, M. Kozakova, K. Hojlund, A. Flyvbjerg, A. Favuzzi et al., Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population, Hepatology, vol.49, p.19291789, 2009.

J. C. Bae, E. J. Rhee, W. Y. Lee, S. E. Park, C. Y. Park et al., Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study, Diabetes Care, vol.34, p.21278140, 2011.

T. Nishi, A. Babazono, T. Maeda, T. Imatoh, and H. Une, Evaluation of the fatty liver index as a predictor for the development of diabetes among insurance beneficiaries with prediabetes, J Diabetes Investig, vol.6, p.25969716, 2015.

J. Franch-nadal, L. Caballeria, M. Mata-cases, M. D. Giraldez-garcia, C. Mancera et al., Fatty liver index is a predictor of incident diabetes in patients with prediabetes: the PREDAPS study, PLoS ONE, vol.13, issue.6, p.29856820, 2018.

J. Lindströ-m and J. Tuomilehto, The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care, vol.26, p.12610029, 2003.

D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher et al., Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, vol.28, issue.7, p.3899825, 1985.

K. Alberti, P. Zimmet, and J. Shaw, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition, The Lancet, vol.366, issue.9491, pp.1059-1062, 2005.

, Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes, Diabetes Care, vol.41, p.29222373, 2018.

H. Tilg, A. R. Moschen, and M. Roden, NAFLD and diabetes mellitus, Nat Rev Gastroenterol Hepatol, vol.14, p.27729660, 2017.

W. Goessling, J. M. Massaro, R. S. Vasan, D. 'agostino, R. B. Sr et al., Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease, Gastroenterology, vol.135, p.19010326, 2008.

D. H. Lee, M. H. Ha, J. H. Kim, D. C. Christiani, M. D. Gross et al., Gamma-glutamyltransferase and diabetes-a 4 year follow-up study, Diabetologia, vol.46, p.12687334, 2003.

A. Fraser, R. Harris, N. Sattar, S. Ebrahim, D. Smith et al., Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis, Diabetes Care, vol.32, p.19131466, 2009.

C. H. Kim, J. Y. Park, K. U. Lee, J. H. Kim, and H. K. Kim, Fatty liver is an independent risk factor for the development of type 2 diabetes in Korean adults, Diabet Med, vol.25, p.18346164, 2008.

B. Balkau, C. Lange, S. Vol, F. Fumeron, and F. Bonnet,

G. Study and D. E. , Nine-year incident diabetes is predicted by fatty liver indices: the French D, E.S.I.R. study. BMC Gastroenterol, vol.10, p.20529259, 2010.

S. Jä-ger, S. Jacobs, J. Krö-ger, S. N. Fritsche, A. Weikert et al., Association between the Fatty Liver Index and Risk of Type 2 Diabetes in the EPIC-Potsdam Study, PLoS One, vol.10, p.25902304, 2015.

, Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2019, Diabetes Care, vol.42, pp.29-33, 2019.

K. C. Sung, S. H. Wild, and C. D. Byrne, Resolution of fatty liver and risk of incident diabetes, J Clin Endocrinol Metab, vol.98, p.23873989, 2013.